According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. “
A number of other equities analysts have also recently issued reports on the company. Morgan Stanley increased their target price on ZEALAND PHARMA/S from $35.00 to $37.00 and gave the stock an overweight rating in a report on Wednesday, April 15th. Needham & Company LLC started coverage on ZEALAND PHARMA/S in a report on Thursday, May 14th. They issued a buy rating and a $42.00 target price on the stock. Finally, ValuEngine upgraded ZEALAND PHARMA/S from a sell rating to a hold rating in a report on Thursday, March 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $40.25.
ZEALAND PHARMA/S stock opened at $32.09 on Friday. ZEALAND PHARMA/S has a 52-week low of $18.75 and a 52-week high of $44.60. The stock’s 50 day moving average price is $36.92 and its two-hundred day moving average price is $35.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.30 and a current ratio of 7.30. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -11.89 and a beta of 1.26.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last issued its earnings results on Thursday, May 14th. The company reported ($4.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($4.35). ZEALAND PHARMA/S had a negative return on equity of 51.41% and a negative net margin of 1,157.20%. The firm had revenue of $1.83 million during the quarter, compared to the consensus estimate of $5.13 million. On average, equities research analysts forecast that ZEALAND PHARMA/S will post -3.07 EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZEAL. Renaissance Technologies LLC raised its position in ZEALAND PHARMA/S by 163.9% in the 4th quarter. Renaissance Technologies LLC now owns 27,978 shares of the company’s stock valued at $929,000 after buying an additional 17,378 shares during the last quarter. Jane Street Group LLC increased its position in shares of ZEALAND PHARMA/S by 22.2% during the 1st quarter. Jane Street Group LLC now owns 16,656 shares of the company’s stock valued at $575,000 after purchasing an additional 3,022 shares during the last quarter. UBS Group AG purchased a new stake in shares of ZEALAND PHARMA/S during the 1st quarter valued at $40,000. Finally, Morgan Stanley increased its position in shares of ZEALAND PHARMA/S by 4.6% during the 1st quarter. Morgan Stanley now owns 14,272 shares of the company’s stock valued at $493,000 after purchasing an additional 631 shares during the last quarter. 6.38% of the stock is owned by institutional investors and hedge funds.
About ZEALAND PHARMA/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Further Reading: Net Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.